spacer
home > white papers > Clinical Trials in Emerging Markets: Goldmines or Landmines? - Pharm-Olam, LLC
WHITE PAPERS
logo_Pharm-Olamo.jpg

Pharm-Olam, LLC

phone +1 (713) 559-7900
email info@pharm-olam.com
web http://www.pharm-olam.com
email 79 T.W. Alexander Drive Building 4401, Suite 240, Research Triangle Park, NC 27709

Clinical Trials in Emerging Markets: Goldmines or Landmines?

Over the past decade, biopharmaceutical companies have increasingly turned to emerging markets as a way to reduce clinical trial costs and timelines. Areas such as Eastern Europe, India, and Latin America—with their ready population of treatment naïve patients—can be an answer to the intense competition for patients seen in developed markets. Many of the countries within these regions may now be considered as “emerged” countries but yet, conducting trials in these regions does require some special attention and expertise. Before deciding to conduct studies in these areas, companies should have a full appreciation for the ethical, medical, regulatory, legal, and operational hurdles that must be surmounted for success. Here we highlight a number of those issues and offer our recommendations for how sponsor companies can deal with them effectively.

The Allure of Emerging Markets Sponsors’ interest in emerging markets as loci for clinical trials has been mounting for at least a decade. (See Figure 1A and 1B.) In 2011, this phenomenon reached a tipping point: for the first time, more data were submitted to the European Medicines Agency in marketing-authorization applications on patients from outside of Europe and North American than from within those areas. While the “Rest of the World” designation includes some mature markets such as Australia and Japan, there is, nonetheless, a clear takeaway: emerging markets have become a hot bed of trial activity.

Clinical Trials in Emerging Markets: Goldmines or Landmines?
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Turkish Cargo maintains its dual-terminal operations seamlessly

Completing the gradual transition process to Istanbul Airport, one of the largest airports of the world, the global air cargo brand Turkish Cargo maintains its dual-terminal operations with full capacity on 7/24 basis without any sales restriction.
More info >>


White Papers

Pharmaceutical Companies: Outsourcing Combination Product Manufacturing

Phillips-Medisize

Combination products are therapeutics that combine two or more products (drug/device, biologics/device, biologics/drugs, or drug/device/biologics), regulated and sold as a single unit. Examples of combination products include drug-coated implantable devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
More info >>


Industry Events

Clinical Trial Supply New England

24-25 March 2020, Boston, US

Following on from another successful conference Arena International will be returning with full force to Waltham in March to celebrate another edition of the Clinical Trial Supply show. 2020 will gather the key stakeholders in the clinical trials community, including the FDA, US Customs and Border Protection, Biogen, Sanofi, and Blueprint Medicines Corporation. With interactive session formats, fresh content and networking, the event will provide attendees with an unparalleled opportunity for collaboration between players across the whole industry.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement